<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02520804</url>
  </required_header>
  <id_info>
    <org_study_id>Si566/2014</org_study_id>
    <nct_id>NCT02520804</nct_id>
  </id_info>
  <brief_title>Normal Saline Versus Balance Salt Solution Resuscitation on Kidney Function</brief_title>
  <official_title>Effect of Normal Saline Versus Balance Salt Solution Resuscitation on Kidney Function; A Randomized Open Label Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mahidol University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine Acute kidney injury incidence between sterofundin
      and normal saline ; Resuscitation shock patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sample size:Compare proportion for independent two groups formula. n=sample size α risk of
      0.05, Statistical power of 80% P1 =incidence of acute kidney injury (AKI) in control (0.6)*
      P2 =incidence of acute kidney injury (AKI) in balanced salt solution (0.4)** from Ratanarat
      R,Hantaweepant C,Tangkawattanakul N,et al.The clinical outcome of acute kidney injury in
      critically ill Thai patients stratified with RIFLE classification.J Med Assoc Thai 2009
      Mar;92 Suppl 2:61-7.

      α risk of 0.05, Statistical power of 80%

      Sample size for interim analysis 1.11 x 97 = 107.67 total 108 (at least 50 cases each arm)
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>acute kidney injury</measure>
    <time_frame>7 day</time_frame>
    <description>Number of Participants with acute kidney injury divided by KIDNEY DISEASE | IMPROVING GLOBAL OUTCOMES (KDIGO) Staging</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Requirement of Renal replacement therapy (RRT)</measure>
    <time_frame>up to 7 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sodium level</measure>
    <time_frame>day 1-3</time_frame>
    <description>change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>potassium level</measure>
    <time_frame>day 1-3</time_frame>
    <description>change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>chloride level</measure>
    <time_frame>day 1-3</time_frame>
    <description>change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bicarbonate level</measure>
    <time_frame>day 1-3</time_frame>
    <description>change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>28-day mortality</measure>
    <time_frame>28 days after admission</time_frame>
    <description>Number of Participants death within 28 day after admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU mortality</measure>
    <time_frame>ICU admission up to 28 day</time_frame>
    <description>Number of Participants death at ICU within 28 day after admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hospital stay</measure>
    <time_frame>during hospital admission up to 28 day</time_frame>
    <description>number of Hospital admission date</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU hospital stay</measure>
    <time_frame>during admission up to 28 day</time_frame>
    <description>number of Hospital admission date</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean arterial pressure</measure>
    <time_frame>day1-3</time_frame>
    <description>mmHg (average)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>dose of norepinephrine</measure>
    <time_frame>day1-3</time_frame>
    <description>(µg/k/min)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>dose of adrenaline</measure>
    <time_frame>day1-3</time_frame>
    <description>(µg/k/min)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">107</enrollment>
  <condition>Acute Kidney Injury</condition>
  <condition>Shock</condition>
  <arm_group>
    <arm_group_label>normal saline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>normal saline for fluid resuscitation and maintenance for 72 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sterofundin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sterofundin for fluid resuscitation and maintenance for 72 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sterofundin</intervention_name>
    <description>sterofundin for shock patients in the first 72 hours</description>
    <arm_group_label>sterofundin</arm_group_label>
    <other_name>balance salt solution</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>normal saline</intervention_name>
    <description>Normal saline for shock patients in the first 72 hours</description>
    <arm_group_label>normal saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Shock patients (hypotension with signs of poor tissue perfusion)

        Exclusion Criteria:

          -  Age &lt; 18 yr

          -  Cardiogenic shock patients (History of ST elevation and Left ventricular ejection
             fraction (LVEF) &lt; 35%),

          -  Prolong shock &gt;24 hrs,

          -  Received chloride rich crystalloid (0.9% saline) or chloride rich colloid &gt; 1000 ml
             within 72 hrs before recruitment

          -  Do-not-resuscitation patients,

          -  Contraindication for IV fluid administration such as pulmonary edema.,

          -  Stage V chronic kidney disease (CKD),

          -  chronic Hemodialysis or Peritonealdialyse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ranistha Ratanarat, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mahidol University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ranistha Ratanarat, MD</last_name>
    <phone>66896685287</phone>
    <email>Ranittha@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mahidol University</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ranistha Rattanarat, MD</last_name>
      <phone>0896685287</phone>
      <email>Ranittha@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <reference>
    <citation>Barber AE, Shires GT. Cell damage after shock. New Horiz. 1996 May;4(2):161-7. Review.</citation>
    <PMID>8774792</PMID>
  </reference>
  <reference>
    <citation>Kristensen SR. Mechanisms of cell damage and enzyme release. Dan Med Bull. 1994 Sep;41(4):423-33. Review.</citation>
    <PMID>7813251</PMID>
  </reference>
  <reference>
    <citation>Kumar A, Parrillo J. Shock: Classification,Pathophysiology, and Approach to Management. In: Dellinger R, Parillo J,eds. Critical Care Medicine: Principles of Diagnosis and Management in the Adult. Philadelphia: Mosby Elsevier,2008.</citation>
  </reference>
  <reference>
    <citation>Marino PL.Inflammatory shock syndrome. In:Marino PL,eds. Marino's The ICU Book 4th edition.Philadelphia:Wolters Kluwer,2014.</citation>
  </reference>
  <reference>
    <citation>Myburgh JA, Mythen MG. Resuscitation fluids. N Engl J Med. 2013 Sep 26;369(13):1243-51. doi: 10.1056/NEJMra1208627. Review.</citation>
    <PMID>24066745</PMID>
  </reference>
  <reference>
    <citation>Martini WZ, Cortez DS, Dubick MA. Comparisons of normal saline and lactated Ringer's resuscitation on hemodynamics, metabolic responses, and coagulation in pigs after severe hemorrhagic shock. Scand J Trauma Resusc Emerg Med. 2013 Dec 11;21:86. doi: 10.1186/1757-7241-21-86.</citation>
    <PMID>24330733</PMID>
  </reference>
  <reference>
    <citation>Chowdhury AH, Cox EF, Francis ST, Lobo DN. A randomized, controlled, double-blind crossover study on the effects of 2-L infusions of 0.9% saline and plasma-lyte® 148 on renal blood flow velocity and renal cortical tissue perfusion in healthy volunteers. Ann Surg. 2012 Jul;256(1):18-24. doi: 10.1097/SLA.0b013e318256be72. Erratum in: Ann Surg. 2013 Dec;258(6):1118.</citation>
    <PMID>22580944</PMID>
  </reference>
  <reference>
    <citation>Guidet B, Soni N, Della Rocca G, Kozek S, Vallet B, Annane D, James M. A balanced view of balanced solutions. Crit Care. 2010;14(5):325. doi: 10.1186/cc9230. Epub 2010 Oct 21. Review.</citation>
    <PMID>21067552</PMID>
  </reference>
  <reference>
    <citation>Perner A, Haase N, Guttormsen AB, Tenhunen J, Klemenzson G, Åneman A, Madsen KR, Møller MH, Elkjær JM, Poulsen LM, Bendtsen A, Winding R, Steensen M, Berezowicz P, Søe-Jensen P, Bestle M, Strand K, Wiis J, White JO, Thornberg KJ, Quist L, Nielsen J, Andersen LH, Holst LB, Thormar K, Kjældgaard AL, Fabritius ML, Mondrup F, Pott FC, Møller TP, Winkel P, Wetterslev J; 6S Trial Group; Scandinavian Critical Care Trials Group. Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis. N Engl J Med. 2012 Jul 12;367(2):124-34. doi: 10.1056/NEJMoa1204242. Epub 2012 Jun 27. Erratum in: N Engl J Med. 2012 Aug 2;367(5):481.</citation>
    <PMID>22738085</PMID>
  </reference>
  <reference>
    <citation>Ratanarat R, Hantaweepant C, Tangkawattanakul N, Permpikul C. The clinical outcome of acute kidney injury in critically ill Thai patients stratified with RIFLE classification. J Med Assoc Thai. 2009 Mar;92 Suppl 2:S61-7.</citation>
    <PMID>19562988</PMID>
  </reference>
  <reference>
    <citation>Yunos NM, Bellomo R, Hegarty C, Story D, Ho L, Bailey M. Association between a chloride-liberal vs chloride-restrictive intravenous fluid administration strategy and kidney injury in critically ill adults. JAMA. 2012 Oct 17;308(15):1566-72. doi: 10.1001/jama.2012.13356.</citation>
    <PMID>23073953</PMID>
  </reference>
  <reference>
    <citation>Shaw AD, Bagshaw SM, Goldstein SL, Scherer LA, Duan M, Schermer CR, Kellum JA. Major complications, mortality, and resource utilization after open abdominal surgery: 0.9% saline compared to Plasma-Lyte. Ann Surg. 2012 May;255(5):821-9. doi: 10.1097/SLA.0b013e31825074f5.</citation>
    <PMID>22470070</PMID>
  </reference>
  <reference>
    <citation>Kidney disease: Improving Global outcomes (KDIGO) Acute kidney injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney injury.Kidney inter., Suppl.2012;2:1-138</citation>
  </reference>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 29, 2015</study_first_submitted>
  <study_first_submitted_qc>August 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2015</study_first_posted>
  <last_update_submitted>March 31, 2016</last_update_submitted>
  <last_update_submitted_qc>March 31, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>balanced salt solution</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

